Human TRAIL R3/TNFRSF10C Affinity Purified Polyclonal Ab (25 UG)【科瑞奥博】

产品中心

当前位置：首页>产品中心

Human TRAIL R3/TNFRSF10C Affinity Purified Polyclonal Ab (25 UG)

货号： AF630-SP 基本售价： 1378.1 元规格： -

产品信息

概述
货号	AF630-SP
别名	Antagonist decoy receptor for TRAIL/Apo-2L; CD263 antigen; CD263; cytotoxic TRAIL receptor-3; DcR1; DCR1MGC149502; Decoy receptor 1; Decoy TRAIL receptor without death domain; LITMGC149501; Lymphocyte inhibitor of TRAIL; TNFRSF10C; TRAIL receptor 3; TRAIL receptor without an intracellular domain; TRAIL-R3; TRAILR3TNF-related apoptosis-inducing ligand receptor 3; TRIDDCR1-TNFR; tumor necrosis factor receptor superfamily member 10C; tumor necrosis factor receptor superfamily, member 10c, decoy without anintracellular domain
全称	TRAIL Receptor 3
反应种属	Human
应用	Western Blot(0.5 µg/mL) Immunohistochemistry(5-15 µg/mL)
目标/特异性	Detects human TRAIL R3/TNFRSF10C in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant human (rh) TRAIL R1, and rhTRAIL R2 is observed.
使用方法	Western Blot: 0.5 µg/mL Immunohistochemistry: 5-15 µg/mL Neutralization: Measured by its ability to neutralize TRAIL R3/TNFRSF10C-mediated inhibition of cytotoxicity in the L‑929 mouse fibroblast cell line. The Neutralization Dose (ND₅₀) is typically 0.015-0.045 µg/mL in the presence of 20 ng/mL Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera, 12 ng/mL of Recombinant Human TRAIL, and 1 µg/mL actinomycin D.
来源	Polyclonal Goat IgG
产品组分

性能
供应商	R&D Systems
Entrez Gene IDs	8794 (Human)
应用文献
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5. Authors: Wu CH, Kao CH, Safa AR Hum. Gene Ther., 2008;19(7):731-43. Species: Human Sample Type: Whole Cells Application: Neut Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. Authors: Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser KB, Okamoto K, Ganslmayer M, Hahn EG, Herold C, Ocker M Int. J. Oncol., 2007;31(6):1391-402. Species: Human Sample Type: Cell Lysates Application: WB P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Authors: Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR Biochem. Pharmacol., 2006;72(3):293-307. Species: Human Sample Type: Whole Cells Application: Flow Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3. Authors: Lane D, Cote M, Grondin R, Couture MC, Piche A Mol. Cancer Ther., 2006;5(3):509-21. Species: Human Sample Type: Whole Cells Application: WB Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Authors: Roux S, Lambert-Comeau P, Saint-Pierre C, Lepine M, Sawan B, Parent JL Biochem. Biophys. Res. Commun., 2005;333(1):42-50. Species: Human Sample Type: Whole Tissue Application: IHC Paraffin-embedded Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Authors: Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P Circ. Res., 2003;92(7):732-40. Species: Human Sample Type: Whole Cells Application: Flow Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Authors: Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC Oncogene, 2002;21(37):5673-83. Species: Human Sample Type: Whole Cells Application: Flow Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells. Authors: Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW, Baker JR Cell Death Differ., 2002;9(3):274-86. Species: Human Sample Type: Whole Cells Application: Flow
纯化方式	Antigen Affinity-purified
免疫原	Mouse myeloma cell line NS0-derived recombinant human TRAIL R3/TNFRSF10C Ala26-Ala221 Accession # O14798
内毒素水平	<0.10 EU per 1 μg of the antibody by the LAL method.
生物活性	Human
标记	Unconjugated
溶解方法	Reconstitute at 0.2 mg/mL in sterile PBS.
背景	Human TRAIL R3, also called DcR1 (decoy receptor 1), LIT, and TRID, is a glycosyl-phosphatidylinositol-linked membrane protein which binds TRAIL (Apo2 Ligand) with high affinity. In the new TNF superfamily nomenclature, TRAIL R3 is referred to as TNFRSF10C. TRAIL R3 has the TRAIL-binding extracellular cysteine-rich domains but lacks the intracellular signalling domain. As a result, binding of TRAIL to TRAIL R3 does not transduce an apoptosis signal. Expression of TRAIL R3 has been shown to protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-induced apoptosis. A second TRAIL decoy receptor, which binds TRAIL with high-affinity but antagonizes TRAIL-induced apoptosis, named TRAIL R4, DcR2 or TRUNDD, has also been reported. The human soluble TRAIL R3/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.
运输条件	Blue Ice
存放说明	4℃
参考文献	Sheridan, J.P.et al. (1997) Science 277:818. Golstein, P. (1997) Curr. Biol. 7:R750.

参考图片

Detection of Human TRAIL R3/TNFRSF10C by Western Blot. Western blot shows lysates of L‑929 mouse fibroblast cell line, THP‑1 human acute monocytic leukemia cell line, and WS‑1 human fetal skin fibroblast cell line. PVDF membrane was probed with 0.5 µg/mL of Goat Anti-Human TRAIL R3/TNFRSF10C Antigen Affinity-purified Polyclonal Antibody (Catalog # AF630) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for TRAIL R3/TNFRSF10C at approximately 27 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

TRAIL R3/TNFRSF10C Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R3/TNFRSF10C Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (5 µg/mL, Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera (Catalog # 630-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375‑TL) induced cytotoxicity in the L‑929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, inhibition of Recombinant Human TRAIL/
TNFSF10 (12 ng/mL) activity elicited by Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera (20 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TRAIL R3/
TNFRSF10C Antigen Affinity-purified Polyclonal Antibody (Catalog # AF630). The ND₅₀ is typically 0.015-0.045 µg/mL.